Nanotherapeutics in transplantation: How do we get to clinical implementation?

Leah Plumblee; Carl Atkinson; Dinesh Jaishankar; Evan Scott; Gregory T. Tietjen; Satish N. Nadig

doi:10.1111/ajt.17012

Nanotherapeutics in transplantation: How do we get to clinical implementation?

Leah Plumblee, Carl Atkinson, Dinesh Jaishankar, Evan Scott, Gregory T. Tietjen, Satish N. Nadig^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Patients undergoing organ transplantation transition from one life-altering issue (organ dysfunction) to a lifelong commitment—immunosuppression. Regimens of immunosuppressive agents (ISAs) come with significant side effects and comorbidities. Recently, the use of nanoparticles (NPs) as a solution to the problems associated with the long-term and systemic use of ISAs in transplantation has emerged. This minireview describes the role of NPs in organ transplantation and discusses obstacles to clinical implementation and pathways to clinical translation.

Original language	English (US)
Pages (from-to)	1293-1298
Number of pages	6
Journal	American Journal of Transplantation
Volume	22
Issue number	5
DOIs	https://doi.org/10.1111/ajt.17012
State	Published - May 2022

Funding

Research reported in this publication was supported by the National Institute of Health (SNN: NIBIB K08EB019495, CA: NHLBI R01HL140470, LP: NIH T32 HL007260, GT: NIDDK R01DK124420).

Keywords

basic (laboratory) research/science
bioengineering
graft survival
immunosuppressant
immunosuppression/immune modulation
organ perfusion and preservation
organ transplantation in general
solid organ transplantation
translational research/science

ASJC Scopus subject areas

Immunology and Allergy
Transplantation
Pharmacology (medical)

Access to Document

10.1111/ajt.17012

Cite this

@article{e78c38e7a8674994afdad59a109d5698,

title = "Nanotherapeutics in transplantation: How do we get to clinical implementation?",

abstract = "Patients undergoing organ transplantation transition from one life-altering issue (organ dysfunction) to a lifelong commitment—immunosuppression. Regimens of immunosuppressive agents (ISAs) come with significant side effects and comorbidities. Recently, the use of nanoparticles (NPs) as a solution to the problems associated with the long-term and systemic use of ISAs in transplantation has emerged. This minireview describes the role of NPs in organ transplantation and discusses obstacles to clinical implementation and pathways to clinical translation.",

keywords = "basic (laboratory) research/science, bioengineering, graft survival, immunosuppressant, immunosuppression/immune modulation, organ perfusion and preservation, organ transplantation in general, solid organ transplantation, translational research/science",

author = "Leah Plumblee and Carl Atkinson and Dinesh Jaishankar and Evan Scott and Tietjen, {Gregory T.} and Nadig, {Satish N.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.",

year = "2022",

month = may,

doi = "10.1111/ajt.17012",

language = "English (US)",

volume = "22",

pages = "1293--1298",

journal = "American Journal of Transplantation",

issn = "1600-6135",

publisher = "Elsevier B.V.",

number = "5",

}

TY - JOUR

T1 - Nanotherapeutics in transplantation

T2 - How do we get to clinical implementation?

AU - Plumblee, Leah

AU - Atkinson, Carl

AU - Jaishankar, Dinesh

AU - Scott, Evan

AU - Tietjen, Gregory T.

AU - Nadig, Satish N.

N1 - Publisher Copyright: © 2022 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.

PY - 2022/5

Y1 - 2022/5

N2 - Patients undergoing organ transplantation transition from one life-altering issue (organ dysfunction) to a lifelong commitment—immunosuppression. Regimens of immunosuppressive agents (ISAs) come with significant side effects and comorbidities. Recently, the use of nanoparticles (NPs) as a solution to the problems associated with the long-term and systemic use of ISAs in transplantation has emerged. This minireview describes the role of NPs in organ transplantation and discusses obstacles to clinical implementation and pathways to clinical translation.

AB - Patients undergoing organ transplantation transition from one life-altering issue (organ dysfunction) to a lifelong commitment—immunosuppression. Regimens of immunosuppressive agents (ISAs) come with significant side effects and comorbidities. Recently, the use of nanoparticles (NPs) as a solution to the problems associated with the long-term and systemic use of ISAs in transplantation has emerged. This minireview describes the role of NPs in organ transplantation and discusses obstacles to clinical implementation and pathways to clinical translation.

KW - basic (laboratory) research/science

KW - bioengineering

KW - graft survival

KW - immunosuppressant

KW - immunosuppression/immune modulation

KW - organ perfusion and preservation

KW - organ transplantation in general

KW - solid organ transplantation

KW - translational research/science

UR - http://www.scopus.com/inward/record.url?scp=85126066646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126066646&partnerID=8YFLogxK

U2 - 10.1111/ajt.17012

DO - 10.1111/ajt.17012

M3 - Review article

C2 - 35224837

AN - SCOPUS:85126066646

SN - 1600-6135

VL - 22

SP - 1293

EP - 1298

JO - American Journal of Transplantation

JF - American Journal of Transplantation

IS - 5

ER -

Nanotherapeutics in transplantation: How do we get to clinical implementation?

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this